Use of heterocyclic compound for treating diseases related to RET genetic change and method therefor
Patent Information
- Application Number
- MYPI2025005696
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-19
AI Technical Summary
Existing RET inhibitors have limited efficacy in treating tumors related to RET gene alteration, strong drug resistance, and safety problems, such as hypertension and hematotoxicity, making it difficult to effectively overcome drug resistance mutations and improve efficacy.
A heterocyclic compound is provided for the preparation of a drug for the treatment of RET altered tumors, including specific compound structures and derivatives thereof, by administration to an individual to achieve the activity of the RET enzyme, in particular dosage and cycles of Adjust as needed, and use a variety of dosing methods to improve efficacy.
This compound has significant efficacy in tumors altered by RET, can effectively inhibit drug resistance mutations, has good tolerance and safety, and has rare adverse events such as hypertension, QT interval prolongation and lymphopenia, and is also used to treat RET+Non- Small cell lung cancer, medullary thyroid carcinoma and other diseases show high objective response rates and disease control rates.
Abstract
Description
Use and method of heterocyclic compounds for treating diseases associated with RET gene alterations
[0001] This application is based on the application with CN application number 202310567443.8 and application date May 19, 2023, and claims its priority. The disclosed content of the CN application is hereby introduced as a whole into this application. Field of the Invention
[0002] The present invention relates to use of heterocyclic compounds in preparing drugs for treating tumors associated with RET changes and a treatment method thereof.
[0003] Background of the Invention
[0004] Protein kinases are enzymes that catalyze protein phosphorylation reactions. By mediating cell signaling, protein phosphorylation regulates cellular physiological activities, such as survival, proliferation, differentiation, apoptosis, and metabolism. Dysfunction of protein kinases is closely associated with many diseases, including tumors, autoimmune diseases, inflammatory responses, central nervous system disorders, cardiovascular disease, and diabetes.
[0005] RET is a proto-oncogene that encodes a transmembrane receptor tyrosine protein kinase, consisting of a cysteine-rich cadherin-like extracellular domain (for ligand binding), a transmembrane region, and an intracellular domain with tyrosine kinase activity. The RET gene is a cell surface signaling receptor that regulates cell differentiation, growth, and migration and is implicated in the pathogenesis of approximately 2% of human cancers.
[0006] Currently, the treatment of RET+ tumors largely follows the recommended treatment guidelines, such as the use of chemoimmunotherapy as the first-line treatment, the use of single chemotherapy or immunotherapy, or the use of marketed RET inhibitors. Second-line and subsequent treatments use single-agent chemotherapy, immunotherapy, and marketed RET inhibitors. Standard chemotherapy and / or immunotherapy have limited efficacy, and long-term administration of marketed RET inhibitors can lead to RET resistance mutations, resulting in adverse reactions such as reduced efficacy, easy relapse, and poor prognosis. Due to the limitations of drug resistance, the therapeutic effects of marketed RET inhibitors are relatively limited, and there are also safety issues such as hypertension and hematotoxicity during the treatment process. Other multi-target drugs used to treat RET gene fusion mutations are not highly targeted to RET gene fusion mutations and their effectiveness is relatively limited.
[0007] Therefore, it is necessary to explore treatment methods and uses of RET inhibitors that have improved safety and efficacy and can overcome drug-resistant mutations.
[0008] SUMMARY OF THE INVENTION
[0009] In one aspect, the present invention provides a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound, for use in the preparation of a medicament for treating RET altered tumors:
[0010] in:
[0011] R 1 is selected from 4-10 membered heterocyclyl and 5-10 membered heteroaryl, each of which is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, halogen, CN, NO2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Hydroxyalkyl, C 1-4 Halogenated alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl and C 3-6 cycloalkoxy;
[0012] R 2 Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, 4-10 membered heterocyclyl and 5-10 membered heteroaryl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, halogen, CN, NO2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Hydroxyalkyl, C 1-4 Halogenated alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl and C 3-6 cycloalkoxy;
[0013] R 3 Selected from H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-4 Hydroxyalkyl, C 1-4 Heteroalkyl and C 3-6 cycloalkyl; and
[0014] X 1 、X 2 and X 3 are each independently selected from CH and N.
[0015] In some embodiments, the present invention provides compound 1, a stereoisomer, tautomer or mixture thereof of compound 1, an N-oxide of compound 1, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of compound 1, or a stable isotope derivative, metabolite or prodrug of compound 1 for the preparation of a medicament for treating RET altered tumors, wherein compound 1 has the following structure:
[0016] For example, the pharmaceutically acceptable salt of Compound 1 is the fumarate of Compound 1.
[0017] In some embodiments, the RET alteration is a RET fusion or a RET mutation.
[0018] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion, and ERC1-RET fusion. In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L, and V804E.
[0019] In some embodiments, the present invention provides a compound of formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound for use in the preparation of a pharmaceutical composition for treating RET+ solid tumors (RET+
[0020] solid tumors) in medicine.
[0021] In some embodiments, the RET+ solid tumors are RET fusion-positive or RET mutation-positive solid tumors.
[0022] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0023] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L, and V804E.
[0024] In some embodiments, the RET fusion-positive or RET mutation-positive solid tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor-resistant solid tumors, and neuroendocrine colorectal cancer (neuroendocrine CRC).
[0025] In some embodiments, the RET fusion-positive or RET mutation-positive solid tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer and inhibitor-resistant solid tumors.
[0026] In some embodiments, the present invention provides a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound for the preparation of a medicament for treating non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor-resistant solid tumors and / or neuroendocrine colorectal cancer (neuroendocrine CRC).
[0027] In some embodiments, the present invention provides a compound of Formula I, a stereoisomer, tautomer, or mixture thereof, an N-oxide, a pharmaceutically acceptable salt, cocrystal, polymorph, or solvate of the compound, or a stable isotopic derivative, metabolite, or prodrug of the compound for the preparation of a medicament for treating non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, and / or inhibitor-resistant solid tumors. In some embodiments, the medicament is a medicament for treating RET+ non-small cell lung cancer, RET+ medullary thyroid carcinoma, RET+ papillary thyroid carcinoma, RET+ pancreatic cancer, RET+ ovarian cancer, and / or inhibitor-resistant solid tumors.
[0028] In some embodiments, the drug is a drug for treating RET fusion-positive non-small cell lung cancer, RET fusion-positive medullary thyroid cancer, RET fusion-positive papillary thyroid cancer, RET fusion-positive pancreatic cancer, RET fusion-positive ovarian cancer, RET fusion-positive neuroendocrine colorectal cancer (neuroendocrine CRC) and / or RET fusion-positive inhibitor-resistant solid tumors.
[0029] In some embodiments, the drug is a drug for treating RET fusion-positive non-small cell lung cancer, RET fusion-positive medullary thyroid cancer, RET fusion-positive papillary thyroid cancer, RET fusion-positive pancreatic cancer, RET fusion-positive ovarian cancer and / or RET fusion-positive inhibitor-resistant solid tumors.
[0030] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0031] In some embodiments, the drug is a drug for treating RET mutation-positive non-small cell lung cancer, RET mutation-positive medullary thyroid cancer, RET mutation-positive papillary thyroid cancer, RET mutation-positive pancreatic cancer, RET mutation-positive ovarian cancer, RET mutation-positive neuroendocrine colorectal cancer (neuroendocrine CRC) and / or RET mutation-positive inhibitor-resistant solid tumors.
[0032] In some embodiments, the drug is a drug for treating RET mutation-positive non-small cell lung cancer, RET mutation-positive medullary thyroid cancer, RET mutation-positive papillary thyroid cancer, RET mutation-positive pancreatic cancer, RET mutation-positive ovarian cancer and / or RET mutation-positive inhibitor-resistant solid tumors.
[0033] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0034] In some embodiments, the inhibitor is a RET inhibitor or an MKI inhibitor.
[0035] In some embodiments, the RET inhibitor is selpercatinib, pralatinib, SY5007, YP01001 or HA121-28.
[0036] In some embodiments, the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
[0037] In some embodiments, the present invention provides the compound of Formula I, the stereoisomers, tautomers or mixtures thereof of the compound, the N-oxide of the compound, the pharmaceutically acceptable salts, cocrystals, polymorphs or solvates of the compound, or the stable isotope derivatives, metabolites or prodrugs of the compound for the preparation of a medicament for the first or second line treatment of RET+ non-small cell lung cancer (NSCLC).
[0038] In some embodiments, the RET+ non-small cell lung cancer (NSCLC) is RET fusion-positive or RET mutation-positive non-small cell lung cancer (NSCLC).
[0039] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0040] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0041] In another aspect, the present invention provides a compound of Formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound, for use in treating RET-altered tumors.
[0042] In some embodiments, the RET-altered tumor is a RET+ solid tumor.
[0043] In some embodiments, the RET+ solid tumors are RET fusion-positive or RET mutation-positive solid tumors.
[0044] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0045] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0046] In some embodiments, the RET+ solid tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, neuroendocrine colorectal cancer (neuroendocrine CRC) and inhibitor resistant solid tumors.
[0047] In some embodiments, the RET+ solid tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, and inhibitor resistant solid tumors.
[0048] In some embodiments, the inhibitor is a RET inhibitor or an MKI inhibitor.
[0049] In some embodiments, the RET inhibitor is septinib, pralsetinib, SY5007, YP01001, or HA121-28.
[0050] In some embodiments, the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
[0051] In some embodiments, the present invention provides a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound, for use in the first or second line of treatment of RET+ non-small cell lung cancer (NSCLC).
[0052] In some embodiments, the RET+ non-small cell lung cancer (NSCLC) is RET fusion-positive or RET mutation-positive non-small cell lung cancer (NSCLC).
[0053] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0054] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0055] In another aspect, the present invention provides a method for treating RET-altered tumors, comprising administering to a subject an effective amount of a compound of Formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound.
[0056] In some embodiments, the daily dosage of the compound of Formula I, the stereoisomers, tautomers or mixtures thereof, the N-oxide of the compound, the pharmaceutically acceptable salts, cocrystals, polymorphs or solvates of the compound, or the stable isotope derivatives, metabolites or prodrugs of the compound is 10-120 mg, for example, 10 mg, 20 mg, 40 mg, 60 mg, 90 mg, 120 mg, 20-120 mg, 30-120 mg, 40-120 mg, 50-120 mg, 60-120 mg, 70-120 mg, 80-120 mg, 90-120 mg, 100-120 mg or 110-120 mg.
[0057] In some embodiments, the compound of Formula I, the stereoisomers, tautomers or mixtures thereof, the N-oxide of the compound, the pharmaceutically acceptable salts, cocrystals, polymorphs or solvates of the compound, or the stable isotope derivatives, metabolites or prodrugs of the compound are administered once every 1-7 days, for example, once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days or once every 7 days.
[0058] In some embodiments, the administration cycle is 40-120 mg per day, administered once a day.
[0059] In some embodiments, the RET-altered tumor is a RET+ solid tumor, such as non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, neuroendocrine colorectal cancer (neuroendocrine CRC), and inhibitor resistant solid tumors.
[0060] In some embodiments, the RET-altered tumor is a RET+ solid tumor, such as non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, and inhibitor-resistant solid tumors.
[0061] In some embodiments, the RET-altered tumor is a RET fusion-positive solid tumor, such as non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor-resistant solid tumors, and neuroendocrine colorectal cancer (neuroendocrine CRC).
[0062] In some embodiments, the RET fusion-positive solid tumor is RET fusion-positive non-small cell lung cancer (NSCLC).
[0063] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0064] In some embodiments, the inhibitor is a RET inhibitor or an MKI inhibitor.
[0065] In some embodiments, the RET inhibitor is septinib, pralsetinib, SY5007, YP01001, or HA121-28.
[0066] In some embodiments, the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
[0067] In some embodiments, the objective response rate (ORR) of a subject administered a therapeutically effective amount of a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound is at least 60%.
[0068] In some embodiments, the objective response rate (ORR) of a subject administered a therapeutically effective amount of the compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound is at least 63%, e.g., 64%.
[0069] In some embodiments, the objective response rate (ORR) of a subject administered a therapeutically effective amount of the compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound is at least 70%, 81%.
[0070] In some embodiments, the disease control rate (DCR) of an individual administered a therapeutically effective amount of the compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound is at least 90%, e.g., 94%, 96%.
[0071] In another aspect, the present invention provides a method for treating RET+ non-small cell lung cancer (NSCLC) in one or more lines of treatment, comprising administering to a subject an effective amount of a compound of Formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound.
[0072] In some embodiments, the RET+ non-small cell lung cancer (NSCLC) is RET fusion-positive or RET mutation-positive non-small cell lung cancer (NSCLC).
[0073] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0074] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0075] In some embodiments, the subject has not received or has received systemic pretreatment, such as anti-PD1 / PD-L1 therapy, other RET inhibitor therapy (such as septinib, pralsetinib, SY5007, YP01001 or HA121-28), MKI inhibitor therapy (such as anlotinib, cabozantinib, apatinib, CX1003) or chemotherapy.
[0076] In some embodiments, the individual has not received or has received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET inhibitor therapy, MKI inhibitor therapy, or chemotherapy.
[0077] In some embodiments, the individual has not received or has received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET selective inhibitor therapy, MKI inhibitor therapy, or chemotherapy.
[0078] In some embodiments, the subject has not received or has received systemic pretreatment, such as anti-PD1 / PD-L1 therapy, seratinib, pralsetinib, SY5007, anlotinib, cabozantinib, apatinib, CX1003, or chemotherapy.
[0079] In some embodiments, the subject has previously received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET inhibitor therapy (such as septinib, pralsetinib, SY5007, YP01001 or HA121-28), MKI inhibitor therapy (such as anlotinib, cabozantinib or apatinib, CX1003) or chemotherapy.
[0080] In some embodiments, the individual has previously received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET selective inhibitor therapy (such as septinib, pralsetinib, or SY5007), MKI inhibitor therapy (such as anlotinib, cabozantinib or apatinib, CX1003), or chemotherapy.
[0081] In some embodiments, the individual has previously received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET selective inhibitor therapy, MKI inhibitor therapy, or chemotherapy.
[0082] In some embodiments, the subject has previously received systemic pretreatment, such as anti-PD1 / PD-L1 therapy, seraceptinib, pralsetinib, SY5007, YP01001, HA121-28, anlotinib, cabozantinib or apatinib, CX1003, or chemotherapy.
[0083] In a preferred embodiment, the individual's median prior treatment is selected from 1-15, such as 1-12, such as 1-10, such as 1-9, such as 1-7, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15.
[0084] In a preferred embodiment, the median prior treatment number of the individual is selected from 1-9, such as 1, 2, 3, 4, 5, 6, 7, 8, 9.
[0085] In some embodiments, the individual has previously received systemic anti-PD1 or PD-L1 therapy.
[0086] In preferred embodiments, the subject has a disease control rate (DCR) of at least 91%.
[0087] In a preferred embodiment, the subject has a disease control rate (DCR) of at least 94%, such as 97%.
[0088] In preferred embodiments, the subject has an objective response rate of at least 60% and a disease control rate of at least 94%.
[0089] In preferred embodiments, the subject has an objective response rate of at least 63% and a disease control rate of at least 91%.
[0090] In preferred embodiments, the subject has an objective response rate of at least 70% and a disease control rate of at least 97%.
[0091] In some embodiments, the individual has non-small cell lung cancer (NSCLC) with brain metastasis, bone metastasis, or liver metastasis.
[0092] In some embodiments, the individual suffers from non-small cell lung cancer (NSCLC) with brain metastasis, and further, the individual has not received radiation therapy.
[0093] In a preferred embodiment, the subject has at least a 17% reduction in measurable lesions in the brain.
[0094] In preferred embodiments, the subject has at least a 47% reduction in measurable lesions in the brain, eg, 80%, 100%.
[0095] In a preferred embodiment, the subject has at least a 69% reduction in measurable lesions in the brain.
[0096] In preferred embodiments, the subject has at least a 47% reduction in measurable lesions in the brain, eg, 80%, 100%, and an overall central nervous system disease control rate (CNSDCR) of 100%.
[0097] In a preferred embodiment, the subject has at least a 17% reduction in measurable lesions in the brain and a 100% overall central nervous system disease control rate (CNSDCR).
[0098] In some embodiments, the individual has previously received treatment with other RET inhibitors (eg, septinib, pralsetinib, SY5007, YP01001, and / or HA121-28).
[0099] In some embodiments, the individual has previously received treatment with other RET inhibitors (eg, septinib, pralsetinib, SY5007, YP01001, or HA121-28).
[0100] In some embodiments, the individual has previously received treatment with other RET selective inhibitors (eg, septitinib, pralsetinib, or SY5007).
[0101] In some embodiments, the individual is a patient who has received treatment with other RET selective inhibitors and developed drug resistance.
[0102] In some embodiments, the resistance is resistance to septinib, pralsetinib and / or SY5007.
[0103] In some embodiments, the objective response rate (ORR) of the individual who has received other RET selective inhibitors is at least 43%, and further, the disease control rate (DCR) of the individual is at least 86%.
[0104] In some embodiments, the objective response rate (ORR) of the individual who has received other RET selective inhibitors is at least 38%, and further, the disease control rate (DCR) of the individual is at least 88%.
[0105] In some embodiments, the individual who has received other RET selective inhibitors is a patient positive for KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and / or ERC1-RET fusion.
[0106] In some embodiments, the individual who has received other RET selective inhibitors is a patient positive for G810S, G810R, G810C, V804M, V804L and / or V804E mutations.
[0107] In some embodiments, the individual has previously received treatment with an MKI inhibitor (eg, anlotinib, cabozantinib, apatinib, CX1003).
[0108] In some embodiments, the individual has previously received chemotherapy.
[0109] In some embodiments, the individual has not received systemic pretreated treatment, such as anti-PD1 / PD-L1 therapy, other RET selective inhibitor therapy (such as septitinib or pralsetinib), or chemotherapy.
[0110] In some embodiments, the objective response rate (ORR) in subjects who have not received prior systemic therapy is at least 60%.
[0111] In some embodiments, the objective response rate (ORR) in subjects who have not received prior systemic therapy is at least 74%, eg, 76%, 77%.
[0112] In some embodiments, the objective response rate (ORR) in subjects who have not received prior systemic therapy is at least 81%.
[0113] In some embodiments, the disease control rate (DCR) in subjects who have not received prior systemic therapy is at least 92%.
[0114] In some embodiments, the disease control rate (DCR) in subjects who have not received prior systemic therapy is at least 96%.
[0115] In some embodiments, the subject who has not received prior systemic therapy is selected from subjects who have not received other RET selective inhibitor treatments.
[0116] In some embodiments, the individual who has not received other RET selective inhibitor treatment is a patient positive for KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and / or ERC1-RET fusion.
[0117] In some embodiments, the individual who has not received other RET selective inhibitor treatment is a patient positive for G810S, G810R, G810C, V804M, V804L and / or V804E mutations.
[0118] In another aspect, the present invention provides a method of treating a patient with a drug, comprising administering to the subject an effective amount of a compound of Formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound, in accordance with an administration regimen comprising one or both of the following:
[0119] (1) a daily dosage of 10-120 mg, such as 20-120 mg, 30-120 mg, 40-120 mg, 50-120 mg, 60-120 mg, 70-120 mg, 80-120 mg, 90-120 mg, 100-120 mg, or 110-120 mg; and / or,
[0120] (2) administration once every 1-7 days, for example, administration once a day, administration once every 2 days, administration once every 3 days, administration once every 4 days, administration once every 5 days, administration once every 6 days, or administration once every 7 days;
[0121] After treatment, the indicators that appear in the individuals are evaluated, and no grade 3 or above treatment-related adverse events (TRAEs) occur, or most reversible treatment-related adverse events (TRAEs) are less than grade 3.
[0122] In some embodiments, the majority is greater than 70%.
[0123] In some embodiments, the majority is greater than 74.4%.
[0124] In some embodiments, the majority is 76.1%.
[0125] In some embodiments, the treatment-related adverse events of less than grade 3 are selected from increased AST aspartate aminotransferase, increased ALT alanine aminotransferase, increased creatinine, increased bilirubin, anemia, constipation, and headache.
[0126] In some embodiments, the treatment-related adverse events of less than grade 3 are selected from increased AST aspartate aminotransferase, increased ALT alanine aminotransferase, increased creatinine, increased bilirubin, constipation, and headache.
[0127] In some embodiments, the grade 3 or higher treatment-related adverse events are selected from increased ALP alkaline phosphatase, increased GGT glutamyl transferase, and intestinal obstruction.
[0128] In preferred embodiments, hypertension, QT prolongation, thrombocytopenia, and lymphopenia are rare (eg, <5%) or low grade.
[0129] In preferred embodiments, hypertension, QT prolongation, and lymphopenia are rare (eg, <5%) or low grade.
[0130] The compounds of this invention demonstrate clear efficacy against RET-altered solid tumors and exhibit potent inhibitory effects against RET-resistant mutations. They can be used to treat individuals resistant to existing selective RET inhibitors and those with central nervous system brain metastases (CNS Mets). Compared to existing RET selective inhibitors, they exhibit improved tolerability and safety, with rare occurrences of hypertension, QT prolongation, thrombocytopenia, and lymphopenia.
[0131] Detailed Description of the Invention
[0132] definition
[0133] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art. References to technology used herein are intended to refer to technology commonly understood in the art, including variations of technology or substitutions of equivalent technology that would be apparent to those skilled in the art. While it is believed that the following terms are well understood by those skilled in the art, the following definitions are set forth to better explain the present invention.
[0134] The terms "comprising," "including," "having," "containing," or "involving," and other variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps, even though the additional unrecited elements or method steps are not necessarily present (i.e., these terms also encompass the terms "consisting essentially of" and "consisting of.").
[0135] As used herein, the term "alkyl" is defined as a linear or branched saturated aliphatic hydrocarbon. In some embodiments, the alkyl group has 1 to 12, such as 1 to 6, carbon atoms. For example, as used herein, the term "C 1-6 Alkyl" and "C 1-4"Alkyl" refers to a linear or branched group having 1 to 6 carbon atoms and 1 to 4 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl), which is optionally substituted by one or more (e.g., 1 to 3) suitable substituents such as halogen (in which case the group is referred to as "haloalkyl") (e.g., CH2F, CHF2, CF3, CCl3, C2F5, C2Cl5, CH2CF3, CH2Cl or -CH2CH2CF3, etc.). The term "C 1-4 "Alkyl" refers to a linear or branched aliphatic hydrocarbon chain of 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
[0136] As used herein, the term "heteroalkyl" refers to an optionally substituted alkyl group having one or more backbone chain atoms selected from atoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, or a combination thereof. Numerical ranges (e.g., C 1-6 Assorted alkyl) refers to the number of carbons in the chain, which in this example includes 1-6 carbon atoms. For example, a -CH2OCH2CH3 group is referred to as a C3 assorted alkyl. Connection to the rest of the molecule can be through heteroatoms or carbon atoms in the assorted alkyl chain.
[0137] As used herein, the term "haloalkyl" refers to an alkyl group substituted by one or more (such as 1 to 3) the same or different halogen atoms. 1-6 Haloalkyl" and "C 1-4 The term "haloalkyl" refers to a haloalkyl group having 1 to 6 carbon atoms and 1 to 4 carbon atoms, for example, -CF3, -C2F5, -CHF2, -CH2F, -CH2CF3, -CH2Cl or -CH2CH2CF3, etc.
[0138] As used herein, the term "hydroxyalkyl" refers to a group in which a hydrogen atom in an alkyl group is replaced by one or more hydroxyl groups, for example, C 1-4 Hydroxyalkyl or C 1-3 Examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, -CH(OH)CH3, -C(CH3)2OH, and the like.
[0139] As used herein, the term "alkoxy" refers to a group having an oxygen atom inserted into an alkyl group (as defined above) at any reasonable position, for example, C 1-6 Alkoxy, C 1-4 Alkoxy or C 1-3 Alkoxy. C 1-6Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy, -CH2-OCH3, and the like, which are optionally substituted with one or more (such as 1 to 3) identical or different substituents.
[0140] As used herein, the term "paracyclic" or "fused ring" refers to a ring system formed by two or more cyclic structures that share two adjacent atoms.
[0141] As used herein, the term "spirocycle" refers to a ring system formed by two or more cyclic structures that share one ring atom with each other.
[0142] As used herein, the term "bridged ring" refers to a ring system formed by two or more cyclic structures sharing two atoms that are not directly connected to each other.
[0143] As used herein, the term "cycloalkyl" refers to a saturated or unsaturated non-aromatic monocyclic or polycyclic (such as bicyclic) hydrocarbon ring group, including but not limited to monocyclic alkyl (such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, etc.) and bicyclic alkyl, including spirocyclic, annular (condensed) or bridged ring systems (i.e., spirocyclic alkyl, annular (condensed) alkyl and bridged cycloalkyl, such as bicyclo [1.1.1] pentyl, bicyclo [2.2.1] heptyl, etc.). In the present invention, cycloalkyl is optionally substituted with one or more (such as 1 to 3) identical or different substituents. The carbon atoms on the cycloalkyl are optionally substituted with oxo (oxo) groups (i.e., forming C=O). The term "C 3-6 "Cycloalkyl" refers to a cycloalkyl group having 3 to 6 ring carbon atoms, which may be a monocyclic alkyl group, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, or a bicyclic alkyl group, such as C 5-8 Spiroalkyl, C 5-8 Bridged cycloalkyl, C 5-8 Condensed cycloalkyl, C 5-6 Spiroalkyl, C 5-6 Bridged cycloalkyl or C 5-6 Fused cycloalkyl.
[0144] As used herein, the term "cycloalkoxy" refers to -O-cycloalkyl, wherein cycloalkyl is as defined above. Representative examples of cycloalkoxy include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0145] As used herein, the term "heterocyclyl" or "heterocycle" refers to a monocyclic or polycyclic (e.g., bis-cyclic, spirocyclic, or bridged) group having 2 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) carbon atoms and one or more (e.g., 1, 2, 3, or 4) heteroatoms, including but not limited to oxygen atoms, nitrogen atoms, and sulfur atoms, wherein the carbon atoms and heteroatoms on the heterocyclyl are optionally substituted with an oxo group (e.g., to form C=O, S(=O), or S(=O)2).
[0146] As used herein, the term "4-10 membered heterocyclyl" means a heterocyclyl containing 4-10 ring atoms, including but not limited to 4-9 membered heterocyclyl, 4-8 membered heterocyclyl, 4-7 membered heterocyclyl, 5-6 membered heterocyclyl, 3-8 membered heterocyclyl, 3-7 membered heterocyclyl, 4-7 membered nitrogen-containing heterocyclyl, 4-7 membered oxygen-containing heterocyclyl, 4-7 membered sulfur-containing heterocyclyl, 5-6 membered nitrogen-containing heterocyclyl, 5-6 membered oxygen-containing heterocyclyl, 5-6 membered sulfur-containing heterocyclyl, etc., wherein each of the "nitrogen-containing heterocyclyl", "oxygen-containing heterocyclyl" and "sulfur-containing heterocyclyl" optionally further contains one or more other heteroatoms selected from oxygen, nitrogen and sulfur. Examples of 4-10 membered heterocyclyls include but are not limited to oxiranyl, aziridine, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, pyrrolidonyl (such as ), imidazolidinyl, pyrazolidinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl.
[0147] As used herein, the term "heteroaryl" or "heteroaromatic ring" refers to a monocyclic or polycyclic aromatic group containing one or more identical or different heteroatoms, including monocyclic heteroaryl groups and bicyclic or polycyclic ring systems containing at least one heteroaromatic ring (an aromatic ring system containing at least one heteroatom), which can have 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, for example 5, 6, 7, 8, 9 or 10 ring atoms. The heteroatom can be oxygen, nitrogen or sulfur. The carbon atoms and heteroatoms on the heteroaryl are optionally substituted with oxo groups (for example, to form C=O, S(=O) or S(=O)2).
[0148] As used herein, the term "5-10 membered heteroaryl" or "5-10 membered heteroaromatic ring" means a heteroaryl group (heteroaromatic ring) containing 5 to 10 (e.g., 5 to 6) ring atoms, including a 5-10 membered nitrogen-containing heteroaryl group, a 5-10 membered oxygen-containing heteroaryl group, a 5-10 membered sulfur-containing heteroaryl group, a 5-6 membered nitrogen-containing heteroaryl group, a 5-6 membered oxygen-containing heteroaryl group, a 5-6 membered sulfur-containing heteroaryl group, etc. The "nitrogen-containing heteroaryl group," "oxygen-containing heteroaryl group," and "sulfur-containing heteroaryl group" each optionally contain one or more other heteroatoms selected from oxygen, nitrogen, and sulfur. Examples include, but are not limited to, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, etc., or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., as well as 5-10 membered cyclic groups containing these groups.
[0149] As used herein, the term "heteroaryl" encompasses a cyclic structure, and the point of connection of the cyclic structure to the other groups can be on any ring in the cyclic structure. Therefore, the heteroaryl groups of the present invention also include, but are not limited to, (mono)heteroaryl and (mono)heteroaryl, (mono)heteroaryl and (mono)heterocyclyl, and (mono)heteroaryl and (mono)cycloalkyl, such as 5-6 membered (mono)heteroaryl and 5-6 membered (mono)heteroaryl, 5-6 membered (mono)heteroarylphenyl, 5-6 membered (mono)heteroaryl and 5-6 membered (mono)heterocyclyl, or 5-6 membered (mono)heteroaryl and C 4-6 (mono)cycloalkyl (e.g., 5-6 membered heteroarylcyclobutyl, 5-6 membered heteroarylcyclopentyl or 5-6 membered heteroarylcyclohexyl), examples of which are not limited to indolyl, isoindolyl, indazolyl, benzimidazole, quinolinyl, isoquinolinyl, wait.
[0150] As used herein, the term "halo" or "halogen" group is defined to include F, Cl, Br, or I.
[0151] The term "substituted" means that one or more (e.g., one, two, three, or four) hydrogen atoms on the designated atom are replaced with a group selected from the indicated group, provided that the designated atom's normal valence is not exceeded in the current context and that the substitution results in a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds.
[0152] If a substituent is described as being "optionally substituted," the substituent may be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of the substituents listed, one or more hydrogens on the carbon (to the extent of any hydrogens present) may be replaced, individually and / or collectively, with independently selected optional substituents. If a nitrogen of a substituent is described as being optionally substituted with one or more of the substituents listed, one or more hydrogens on the nitrogen (to the extent of any hydrogens present) may each be replaced with an independently selected optional substituent.
[0153] If substituents are described as being "independently selected" from a group, each substituent is selected independently of the other. Thus, each substituent may be the same as or different from another (other) substituent.
[0154] As used herein, the term "one or more" means 1 or more than 1, such as 2, 3, 4, 5 or 10, where reasonable.
[0155] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.
[0156] When a bond to a substituent is shown to pass through a bond connecting two atoms in a ring, then such substituent may be bonded to any ring atom in the substitutable ring.
[0157] The present invention also includes all pharmaceutically acceptable isotopically labeled compounds, which are identical to the compounds of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Examples of isotopes suitable for inclusion in the compounds of the present invention include, but are not limited to, isotopes of hydrogen (e.g., deuterium ( 2 H), tritium ( 3 H)); carbon isotopes (e.g. 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 36 Cl); isotopes of fluorine (e.g. 18 F); isotopes of iodine (such as 123 I and 125 I); isotopes of nitrogen (e.g. 13 N and 15 N); oxygen isotopes (e.g. 15 O. 17 O and 18 O); isotopes of phosphorus (such as 32 P); and sulfur isotopes (e.g. 35S). Certain isotopically labeled compounds of the invention (e.g., those incorporating radioactive isotopes) are useful in drug and / or substrate tissue distribution studies (e.g., assays). The radioactive isotope tritium (i.e., 3 H) and carbon-14 (i.e. 14 C) are particularly useful for this purpose because they are easy to incorporate and easy to detect. 11 C. 18 F. 15 O and 13 N) substitution can be used to examine substrate receptor occupancy in positron emission tomography (PET) studies. Isotopically labeled compounds of the present invention can be prepared by methods analogous to those described in the accompanying schemes and / or examples and preparations by using appropriate isotopically labeled reagents instead of the non-labeled reagents previously employed. Pharmaceutically acceptable solvates of the present invention include those in which the crystallization solvent is isotopically substituted, for example, D2O, acetone-d6 or DMSO-d6.
[0158] The term "stereoisomer" refers to an isomer formed due to at least one asymmetric center. In a compound with one or more (e.g., one, two, three, or four) asymmetric centers, it can produce an external / meso mixture, a single enantiomer, a diastereomeric mixture, and a separate diastereomer. Specific individual molecules can also exist as geometric isomers (cis / trans). Similarly, the compounds of the present invention can exist as mixtures (commonly referred to as tautomers) of two or more structurally different forms in rapid equilibrium. Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. For example, nitroso-oxime can exist in the following tautomeric form equilibrium in solution:
[0159] It is to be understood that the scope of this application encompasses all such isomers in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%) or mixtures thereof.
[0160] In this article, solid lines can be used Solid wedge or virtual wedge The chemical bonds of the compounds of the present invention are depicted. The use of solid lines to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers at that carbon atom are included (e.g., specific enantiomers, racemic mixtures, etc.). The use of solid or dashed wedges to depict bonds to asymmetric carbon atoms is intended to indicate that the indicated stereoisomers exist. When present in a racemic mixture, solid and dashed wedges are used to define relative stereochemistry, not absolute stereochemistry. Unless otherwise indicated, the compounds of the present invention are intended to exist as stereoisomers, including cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof. The compounds of the present invention may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereomeric pairs).
[0161] The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be single polymorphs or mixtures of more than one polymorph in any ratio.
[0162] A cocrystal refers to a drug active molecule and other physiologically acceptable acid, base, salt, or non-ionic compound molecules bound in the same crystal lattice by hydrogen bonds, π-π stacking, van der Waals forces, and other non-covalent bonds.
[0163] It should also be understood that certain compounds of the present invention may be used therapeutically in free form or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, N-oxides, metabolites, or prodrugs that, upon administration to a patient in need thereof, are capable of directly or indirectly providing a compound of the present invention or a metabolite or residue thereof. Therefore, when reference is made herein to a "compound of the present invention," such various derivative forms of the compound are also intended to be encompassed.
[0164] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof, such as hexafluorophosphate salts and meglumine salts. For a review of suitable salts, see Stahl and Wermuth, "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, 2002).
[0165] As used herein, the term "ester" refers to esters derived from the compounds of the general formulae herein, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release the compounds of the present invention in the form of free acid or alcohol). The compounds of the present invention themselves may also be esters.
[0166] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.
[0167] Those skilled in the art will appreciate that, because nitrogen requires available lone pairs of electrons to be oxidized to oxides, not all nitrogen-containing heterocycles can form N-oxides. Those skilled in the art will recognize nitrogen-containing heterocycles that can form N-oxides. Those skilled in the art will also recognize that tertiary amines can form N-oxides. The synthetic method for preparing the N-oxide of heterocycles and tertiary amines is well known to those skilled in the art, including but not limited to oxidizing heterocycles and tertiary amines with peroxyacids such as Peracetic Acid and Metachloroperbenzoic Acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate and dioxirane such as dimethyldioxirane. These methods for preparing N-oxides have been extensively described and reviewed in the literature, see for example: TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; AR Katritzky and AJ Boulton, Eds., Academic Press; and GWH Cheeseman and ESGWerstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, AR Katritzky and AJ Boulton, Eds., Academic Press.
[0168] Also included within the scope of the present invention are metabolites of the compounds of the invention, i.e., substances formed in vivo upon administration of the compounds of the invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc. of the administered compound. Thus, the present invention includes metabolites of the compounds of the invention, including compounds produced by contacting a compound of the invention with a mammal for a period of time sufficient to produce a metabolic product thereof.
[0169] The present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may themselves have little or no pharmacological activity and can be converted into compounds of the present invention having the desired activity by, for example, hydrolytic cleavage when administered to the body or thereon. Typically, such prodrugs will be functional group derivatives of the compounds that are readily converted into the desired therapeutically active compounds in vivo. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems", Volume 14, ACS Symposium Series (T. Higuchi and V. Stella). Prodrugs of the present invention can be prepared, for example, by replacing appropriate functional groups present in the compounds of the present invention with certain moieties known to those skilled in the art as "pro-moieties" (e.g., as described in "Design of Prodrugs", H. Bundgaard (Elsevier, 1985)).
[0170] The present invention also encompasses compounds of the present invention that contain protecting groups. During any process for preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved using conventional protecting groups, for example, those described in TW Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.
[0171] The term "about" means within ±10%, preferably within ±5%, and more preferably within ±2% of the stated numerical value.
[0172] In the present invention, "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle that is administered together with the therapeutic agent and is suitable for contact with the tissues of humans and / or other animals without excessive toxicity, irritation, allergic response or other problems or complications corresponding to a reasonable benefit / risk ratio within the scope of reasonable medical judgment.
[0173] Pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, sterile liquids. Examples of suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1990).
[0174] The compounds of the present invention or pharmaceutical compositions comprising the same can act systemically and / or locally. For this purpose, they can be administered by any suitable route.
[0175] For these administration routes, the compounds of the present invention or pharmaceutical compositions containing the same can be administered in suitable dosage forms.
[0176] As used herein, the term "effective amount" refers to that amount of a compound which, when administered, will relieve to some extent one or more of the symptoms of the condition being treated.
[0177] The dosage regimen can be adjusted to provide the optimal desired response. For example, a single bolus can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. It is to be noted that dosage values can vary with the type and severity of the condition to be alleviated and can include single or multiple doses. It is to be further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering or supervising the administration of the composition.
[0178] The amount of the compound of the present invention administered will depend on the severity of the individual, disease or the patient's condition, the speed of administration, the disposal of the compound and the judgment of the prescribing physician for treatment. Generally speaking, effective dose is about 0.0001 to about 50 mg per kg body weight per day. In some cases, the dosage level not higher than the lower limit of the aforementioned range can be enough, and in other cases, still can adopt larger doses when not causing any harmful side effects, condition is first divided into several smaller doses to be administered throughout the day.
[0179] The compound of the present invention may be present in the pharmaceutical composition in an amount ranging from about 0.01 mg to about 1000 mg.
[0180] As used herein, unless otherwise indicated, the term "treating" means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
[0181] As used herein, "subject" includes humans and non-human animals. Exemplary human subjects include human subjects suffering from diseases (e.g., the diseases described herein) (referred to as patients) or normal individuals. "Non-human animals" herein include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0182] In some embodiments, the compounds of the present invention can be administered in combination with one or more additional therapeutic or prophylactic agents (e.g., other drugs used to treat cancer or tumor diseases). In some embodiments, the methods of the present invention can also include administering one or more additional therapeutic or prophylactic agents (e.g., other drugs used to treat cancer or tumor diseases).
[0183] Pharmaceutical uses and treatments
[0184] The present invention provides a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound, and use thereof in the preparation of a medicament for treating RET-altered tumors:
[0185] in:
[0186] R 1 is selected from 4-10 membered heterocyclyl and 5-10 membered heteroaryl, each of which is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, halogen, CN, NO2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Hydroxyalkyl, C 1-4 Halogenated alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl and C 3-6 cycloalkoxy;
[0187] R 2 Selected from halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Heteroalkyl, 4-10 membered heterocyclyl and 5-10 membered heteroaryl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, halogen, CN, NO2, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 1-4 Hydroxyalkyl, C 1-4 Halogenated alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl and C 3-6 cycloalkoxy;
[0188] R 3 Selected from H, halogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-4 Hydroxyalkyl, C1-4 Heteroalkyl and C 3-6 cycloalkyl; and
[0189] X 1 、X 2 and X 3 are each independently selected from CH and N.
[0190] In some embodiments, the present invention provides compound 1, a stereoisomer, tautomer or mixture thereof of compound 1, an N-oxide of compound 1, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of compound 1, or a stable isotope derivative, metabolite or prodrug of compound 1 for the preparation of a medicament for treating RET-altered tumors, wherein compound 1 has the following structure:
[0191] For example, the pharmaceutically acceptable salt of Compound 1 is the fumarate of Compound 1.
[0192] In some embodiments, the RET alteration is a RET fusion or a RET mutation.
[0193] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0194] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L, and V804E.
[0195] In some embodiments, the present invention provides a compound of formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound for use in the preparation of a pharmaceutical composition for treating RET+ solid tumors (RET+
[0196] solid tumors) in medicine.
[0197] In some embodiments, the RET+ solid tumors are RET fusion-positive or RET mutation-positive solid tumors.
[0198] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0199] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L, and V804E.
[0200] In some embodiments, the RET fusion-positive or RET mutation-positive solid tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor-resistant solid tumors, and neuroendocrine colorectal cancer (neuroendocrine CRC).
[0201] In some embodiments, the RET fusion-positive or RET mutation-positive solid tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer and inhibitor-resistant solid tumors.
[0202] In some embodiments, the present invention provides a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound for the preparation of a medicament for treating non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor-resistant solid tumors and / or neuroendocrine colorectal cancer (neuroendocrine CRC).
[0203] In some embodiments, the present invention provides a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound for the preparation of a medicament for treating non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, and inhibitor resistant solid tumors.
[0204] In some embodiments, the drug is a drug for treating RET+ non-small cell lung cancer, RET+ medullary thyroid cancer, RET+ papillary thyroid cancer, RET+ pancreatic cancer, RET+ ovarian cancer, and inhibitor-resistant solid tumors.
[0205] In some embodiments, the drug is a drug for treating RET fusion-positive non-small cell lung cancer, RET fusion-positive medullary thyroid cancer, RET fusion-positive papillary thyroid cancer, RET fusion-positive pancreatic cancer, RET fusion-positive ovarian cancer, RET fusion-positive neuroendocrine colorectal cancer (neuroendocrine CRC), and RET fusion-positive inhibitor-resistant solid tumors.
[0206] In some embodiments, the drug is a drug for treating RET fusion-positive non-small cell lung cancer, RET fusion-positive medullary thyroid cancer, RET fusion-positive papillary thyroid cancer, RET fusion-positive pancreatic cancer, RET fusion-positive ovarian cancer, and RET fusion-positive inhibitor-resistant solid tumors.
[0207] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0208] In some embodiments, the drug is a drug for treating RET mutation-positive non-small cell lung cancer, RET mutation-positive medullary thyroid cancer, RET mutation-positive papillary thyroid cancer, RET mutation-positive pancreatic cancer, RET mutation-positive ovarian cancer, RET mutation-positive neuroendocrine colorectal cancer (neuroendocrine CRC), and RET mutation-positive inhibitor-resistant solid tumors.
[0209] In some embodiments, the drug is a drug for treating RET mutation-positive non-small cell lung cancer, RET mutation-positive medullary thyroid cancer, RET mutation-positive papillary thyroid cancer, RET mutation-positive pancreatic cancer, RET mutation-positive ovarian cancer, and RET mutation-positive inhibitor-resistant solid tumors.
[0210] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0211] In some embodiments, the inhibitor is a RET inhibitor or an MKI inhibitor.
[0212] In some embodiments, the RET inhibitor is septinib, pralsetinib, SY5007, YP01001, or HA121-28.
[0213] In some embodiments, the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
[0214] In some embodiments, the present invention provides the compound of Formula I, the stereoisomers, tautomers or mixtures thereof of the compound, the N-oxide of the compound, the pharmaceutically acceptable salts, cocrystals, polymorphs or solvates of the compound, or the stable isotope derivatives, metabolites or prodrugs of the compound for the preparation of a medicament for the first or second line treatment of RET+ non-small cell lung cancer (NSCLC).
[0215] In some embodiments, the RET+ non-small cell lung cancer (NSCLC) is RET fusion-positive or RET mutation-positive non-small cell lung cancer (NSCLC).
[0216] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0217] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0218] In another aspect, the present invention provides a compound of Formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound, for use in treating RET-altered tumors.
[0219] In some embodiments, the RET-altered tumor is a RET+ solid tumor.
[0220] In some embodiments, the RET+ solid tumors are RET fusion-positive or RET mutation-positive solid tumors.
[0221] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0222] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0223] In some embodiments, the RET+ solid tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, neuroendocrine colorectal cancer (neuroendocrine CRC) and inhibitor resistant solid tumors.
[0224] In some embodiments, the RET+ solid tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, and inhibitor resistant solid tumors.
[0225] In some embodiments, the inhibitor is a RET inhibitor or an MKI inhibitor.
[0226] In some embodiments, the RET inhibitor is septinib, pralsetinib, SY5007, YP01001, or HA121-28.
[0227] In some embodiments, the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
[0228] In some embodiments, the present invention provides a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound, for use in the first or second line of treatment of RET+ non-small cell lung cancer (NSCLC).
[0229] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0230] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0231] In another aspect, the present invention provides a method for treating RET-altered tumors, comprising administering to a subject an effective amount of a compound of Formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound.
[0232] In some embodiments, the daily dosage of the compound of Formula I, the stereoisomers, tautomers or mixtures thereof, the N-oxide of the compound, the pharmaceutically acceptable salts, cocrystals, polymorphs or solvates of the compound, or the stable isotope derivatives, metabolites or prodrugs of the compound is 10-120 mg, for example, 10 mg, 20 mg, 40 mg, 60 mg, 90 mg, 120 mg, 20-120 mg, 30-120 mg, 40-120 mg, 50-120 mg, 60-120 mg, 70-120 mg, 80-120 mg, 90-120 mg, 100-120 mg or 110-120 mg.
[0233] In some embodiments, the compound of Formula I, the stereoisomers, tautomers or mixtures thereof, the N-oxide of the compound, the pharmaceutically acceptable salts, cocrystals, polymorphs or solvates of the compound, or the stable isotope derivatives, metabolites or prodrugs of the compound are administered once every 1-7 days, for example, once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days or once every 7 days.
[0234] In some embodiments, the administration cycle is 40-120 mg per day, administered once a day.
[0235] In some embodiments, the RET-altered tumor is a RET+ solid tumor, such as non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, neuroendocrine colorectal cancer (neuroendocrine CRC), and inhibitor resistant solid tumors.
[0236] In some embodiments, the RET-altered tumor is a RET+ solid tumor, such as non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), pancreatic cancer, ovarian cancer, and inhibitor-resistant solid tumors.
[0237] In some embodiments, the RET-altered tumor is a RET fusion-positive solid tumor, such as non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor-resistant solid tumors, and neuroendocrine colorectal cancer (neuroendocrine CRC).
[0238] In some embodiments, the RET fusion-positive solid tumor is RET fusion-positive non-small cell lung cancer (NSCLC).
[0239] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0240] In some embodiments, the inhibitor is a RET inhibitor or an MKI inhibitor.
[0241] In some embodiments, the RET inhibitor is septinib, pralsetinib, SY5007, YP01001, or HA121-28.
[0242] In some embodiments, the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
[0243] In some embodiments, the objective response rate (ORR) of a subject administered a therapeutically effective amount of the compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound is at least 63%, e.g., 64%.
[0244] In some embodiments, the objective response rate (ORR) of a subject administered a therapeutically effective amount of a compound of Formula I, a stereoisomer, tautomer or mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound is at least 70%.
[0245] In another aspect, the present invention provides a method for treating RET+ non-small cell lung cancer (NSCLC) in one or more lines of treatment, comprising administering to a subject an effective amount of a compound of Formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound.
[0246] In some embodiments, the RET+ non-small cell lung cancer (NSCLC) is RET fusion-positive or RET mutation-positive non-small cell lung cancer (NSCLC).
[0247] In some embodiments, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion.
[0248] In some embodiments, the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
[0249] In some embodiments, the subject has not received or has received systemic pretreatment, such as anti-PD1 / PD-L1 therapy, other RET inhibitor therapy (such as septinib, pralsetinib, SY5007, YP01001 or HA121-28), MKI inhibitor therapy (such as anlotinib, cabozantinib, apatinib, CX1003) or chemotherapy.
[0250] In some embodiments, the individual has not received or has received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET inhibitor therapy, MKI inhibitor therapy, or chemotherapy.
[0251] In some embodiments, the individual has not received or has received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET selective inhibitor therapy, MKI inhibitor therapy, or chemotherapy.
[0252] In some embodiments, the subject has not received or has received systemic pretreatment, such as anti-PD1 / PD-L1 therapy, seratinib, pralsetinib, SY5007, YP01001, HA121-28, anlotinib, cabozantinib, apatinib, CX1003, or chemotherapy.
[0253] In some embodiments, the subject has previously received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET inhibitor therapy (such as septinib, pralsetinib, SY5007, YP01001 or HA121-28), MKI inhibitor therapy (such as anlotinib, cabozantinib or apatinib, CX1003) or chemotherapy.
[0254] In some embodiments, the individual has previously received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET selective inhibitor therapy (such as septinib, pralsetinib, or SY5007), MKI inhibitor therapy (such as anlotinib, cabozantinib or apatinib, CX1003), or chemotherapy.
[0255] In some embodiments, the individual has previously received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 therapy, other RET selective inhibitor therapy, MKI inhibitor therapy, or chemotherapy.
[0256] In some embodiments, the subject has previously received systemic pretreatment, such as anti-PD1 / PD-L1 therapy, seraceptinib, pralsetinib, SY5007, YP01001, HA121-28, anlotinib, cabozantinib or apatinib, CX1003, or chemotherapy.
[0257] In a preferred embodiment, the individual's median prior treatment is selected from 1-15, such as 1-12, such as 1-10, such as 1-9, such as 1-7, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15.
[0258] In a preferred embodiment, the median prior treatment number of the individual is selected from 1-9, such as 1, 2, 3, 4, 5, 6, 7, 8, 9.
[0259] In some embodiments, the individual has previously received systemic anti-PD1 or PD-L1 therapy.
[0260] In preferred embodiments, the subject has a disease control rate (DCR) of at least 91%.
[0261] In preferred embodiments, the subject has a disease control rate (DCR) of at least 97%.
[0262] In preferred embodiments, the subject has an objective response rate of at least 63% and a disease control rate of at least 91%.
[0263] In preferred embodiments, the subject has an objective response rate of at least 70% and a disease control rate of at least 97%.
[0264] In some embodiments, the individual has non-small cell lung cancer (NSCLC) with brain metastasis, bone metastasis, or liver metastasis.
[0265] In some embodiments, the individual suffers from non-small cell lung cancer (NSCLC) with brain metastasis, and further, the individual has not received radiation therapy.
[0266] In preferred embodiments, the subject has at least a 47% reduction in measurable lesions in the brain, eg, 80%, 100%.
[0267] In a preferred embodiment, the subject has at least a 69% reduction in measurable lesions in the brain.
[0268] In preferred embodiments, the subject has at least a 47% reduction in measurable lesions in the brain, eg, 80%, 100%, and an overall central nervous system disease control rate (CNSDCR) of 100%.
[0269] In a preferred embodiment, the subject has at least a 69% reduction in measurable lesions in the brain and a 100% overall central nervous system disease control rate (CNSDCR).
[0270] In some embodiments, the individual has previously received treatment with other RET inhibitors (eg, septinib, pralsetinib, SY5007, YP01001, or HA121-28).
[0271] In some embodiments, the individual is a patient who has received treatment with other RET selective inhibitors and developed drug resistance.
[0272] In some embodiments, the resistance is resistance to septinib, pralsetinib and / or SY5007.
[0273] In some embodiments, the objective response rate (ORR) of the individual who has received other RET selective inhibitors is at least 43%, and further, the disease control rate (DCR) of the individual is at least 86%.
[0274] In some embodiments, the objective response rate (ORR) of the individual who has received other RET selective inhibitors is at least 38%, and further, the disease control rate (DCR) of the individual is at least 88%.
[0275] In some embodiments, the individual who has received other RET selective inhibitors is a patient positive for KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and / or ERC1-RET fusion.
[0276] In some embodiments, the individual who has received other RET selective inhibitors is a patient positive for G810S, G810R, G810C, V804M, V804L and / or V804E mutations.
[0277] In some embodiments, the individual has previously received treatment with an MKI inhibitor (eg, anlotinib, cabozantinib, apatinib, CX1003).
[0278] In some embodiments, the individual has previously received chemotherapy.
[0279] In some embodiments, the individual has not received systemic pretreated treatment, such as anti-PD1 / PD-L1 therapy, other RET selective inhibitor therapy (such as septitinib or pralsetinib), or chemotherapy.
[0280] In some embodiments, the objective response rate (ORR) in subjects who have not received prior systemic therapy is at least 60%.
[0281] In some embodiments, the objective response rate (ORR) in subjects who have not received prior systemic therapy is at least 74%, eg, 76%, 77%.
[0282] In some embodiments, the objective response rate (ORR) in subjects who have not received prior systemic therapy is at least 81%.
[0283] In some embodiments, the disease control rate (DCR) in subjects who have not received prior systemic therapy is at least 92%.
[0284] In some embodiments, the disease control rate (DCR) in subjects who have not received prior systemic therapy is at least 96%.
[0285] In some embodiments, the subject who has not received systemic treatment is selected from subjects who have not received other RET selective inhibitor treatments.
[0286] In some embodiments, the individual who has not received other RET selective inhibitor treatment is a patient positive for KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and / or ERC1-RET fusion.
[0287] In some embodiments, the individual who has not received other RET selective inhibitor treatment is a patient positive for G810S, G810R, G810C, V804M, V804L and / or V804E mutations.
[0288] In another aspect, the present invention provides a method of treating a patient with a drug, comprising administering to the subject an effective amount of a compound of Formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotopic derivative, metabolite or prodrug of the compound, in accordance with an administration regimen comprising one or both of the following:
[0289] (1) a daily dosage of 10-120 mg, such as 20-120 mg, 30-120 mg, 40-120 mg, 50-120 mg, 60-120 mg, 70-120 mg, 80-120 mg, 90-120 mg, 100-120 mg, or 110-120 mg; and / or,
[0290] (2) administration once every 1-7 days, for example, administration once a day, administration once every 2 days, administration once every 3 days, administration once every 4 days, administration once every 5 days, administration once every 6 days, or administration once every 7 days;
[0291] After treatment, the indicators occurring in the individuals were evaluated, and no treatment-related adverse events (TRAEs) of grade 3 or above occurred, or most (e.g., 74.4%) reversible treatment-related adverse events (TRAEs) were less than grade 3.
[0292] In some embodiments, the majority is 76.1%.
[0293] In some embodiments, the treatment-related adverse events of less than grade 3 are selected from increased AST aspartate aminotransferase, increased ALT alanine aminotransferase, increased creatinine, increased bilirubin, anemia, constipation, and headache.
[0294] In some embodiments, the treatment-related adverse events of less than grade 3 are selected from increased AST aspartate aminotransferase, increased ALT alanine aminotransferase, increased creatinine, increased bilirubin, constipation, and headache.
[0295] In some embodiments, the grade 3 or higher treatment-related adverse events are selected from increased ALP alkaline phosphatase, increased GGT glutamyl transferase, and intestinal obstruction.
[0296] In preferred embodiments, hypertension, QT prolongation, thrombocytopenia, and lymphopenia are rare (eg, <5%) or low grade.
[0297] In preferred embodiments, hypertension, QT prolongation, and lymphopenia are rare (eg, <5%) or low grade.
[0298] In some embodiments, the compound has the structure shown in Formula IA:
[0299] where R 1 、R 2 、R 3 、X 1 and X 2 As defined above for Formula I.
[0300] In some embodiments, the compound has the structure shown in Formula IB:
[0301] where R 1 、R 2 、R 3 、X 1 and X 2 As defined above for Formula I.
[0302] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 1 is a 5-10 membered heteroaryl group, which is optionally substituted by one or more substituents independently selected from the group consisting of hydroxy, halogen, CN, C 1-4 Alkyl, C 1-4 Halogenated alkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy.
[0303] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 1 is a 5-6 membered heteroaryl group, which is optionally substituted by one or more substituents independently selected from the following: halogen, C 1-3 Alkyl and C 3-6 Cycloalkyl.
[0304] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 1 is pyrazolyl, said pyrazolyl being optionally substituted by one or more substituents independently selected from the group consisting of halogen, C 1-3 Alkyl (such as methyl) and C 3-6 Cycloalkyl (eg, cyclopropyl).
[0305] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 1 It is methyl-substituted pyrazolyl (e.g., 5-methyl-1H-pyrazol-3-yl or 1-methyl-1H-pyrazol-4-yl) or cyclopropyl-substituted pyrazolyl (e.g., 5-cyclopropyl-1H-pyrazol-3-yl).
[0306] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 2 Selected from halogen (such as Cl), C 1-6 alkyl (eg methyl) and 5-6 membered heteroaryl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy.
[0307] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 2 is a 5-6 membered heteroaryl group, which is optionally substituted by one or more substituents independently selected from the following: halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy.
[0308] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 2 is a 5-membered heteroaryl group, which is optionally substituted by one or more substituents independently selected from the following: halogen, C 1-4 Alkyl, C1-4 Hydroxyalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy.
[0309] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 2 is pyrrolyl, pyrazolyl, imidazolyl, furyl or thiazolyl, optionally substituted by one or more substituents independently selected from the group consisting of F, Cl, methyl, Cyclopropyl and -O-cyclopropyl.
[0310] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 3 Selected from H, C 1-6 Alkyl and C 3-6 Cycloalkyl.
[0311] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 3 Selected from H and C 1-6 alkyl.
[0312] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, R 3 is H or methyl.
[0313] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, wherein X 1 is CH or N; preferably, X 1 is N.
[0314] In certain embodiments, the present invention provides the use of compounds of formula I, formula IA and formula IB, wherein X 2 is CH or N; preferably, X 2 For CH.
[0315] In certain embodiments, in the use of the compound of formula I provided by the present invention, X 3 is CH or N; preferably, X 3 is N.
[0316] The present invention covers any combination of the above embodiments.
[0317] In some embodiments, the compounds include, but are not limited to:
[0318] In some embodiments, the compound is:
[0319] In some embodiments, the compound is:
[0320] In some embodiments, the pharmaceutically acceptable salt is a fumarate. In some embodiments, the pharmaceutically acceptable salt of the compound is:
[0321] In some embodiments, the pharmaceutically acceptable salt of the compound is: Example
[0322] The present invention is further described below with reference to examples, but these examples are not intended to limit the scope of the present invention.
[0323] The compound of the present invention is separated and purified by preparative TLC, silica gel column chromatography, Prep-HPLC and / or flash column chromatography (Flash column chromatography). 1 The reaction was confirmed by H NMR and / or MS. Reaction monitoring was performed by TLC or LC-MS.
[0324] 1 H NMR spectroscopy was performed using a Bruker superconducting nuclear magnetic resonance spectrometer (model AVACE III HD 400 MHz).
[0325] LC / MS uses Aglient 1260Infinity / Aglient 6120 Quadrupole.
[0326] TLC used silica gel GF 254 as the stationary phase.
[0327] Column chromatography generally uses 200-300 mesh silica gel (Qingdao Ocean) as the stationary phase.
[0328] Flash column chromatography was performed using a Biotage flash column chromatograph.
[0329] Prep-HPLC was performed using Agilent 1260, Waters 2489 and GeLai 3500 chromatographs.
[0330] Microwave reactions were performed using a BiotageInitiator microwave reactor.
[0331] In the following examples, unless otherwise specified, the reaction temperature is room temperature (15-30°C).
[0332] The reagents used in this application were purchased from Acros Organics, Aldrich Chemical Company, or Teber Chemical Company.
[0333] Example: Fumarate Salt of 2-(6-(6-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyridin-3-yl)-6-methyl-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (Compound 1-A)
[0334] Compound 1 (5 g) was dissolved in 200 mL of THF. After stirring until completely dissolved, 1.56 g of fumaric acid was slowly added and the mixture was allowed to react at 20-45°C for 46 h. After completion of the reaction, the mixture was filtered and washed with THF to yield 7.06 g of a wet solid. This was then dried in vacuo at 40-45°C to yield 4.78 g of a solid powder.
[0335] 1 H NMR (400MHz, DMSO-d6) δ12.43(br,3H),9.66(s,1H),9.13(d,J=2.4Hz,1H),8.60(d,J=4.4Hz,1H), 8.44(dd,J=8.8,2.4Hz,1H),8.41(d,J=1.2Hz,1H),7.97(dd,J=8.4,2.0Hz,1H),7.91(d,J=4.4Hz,1 H),7.86(d,J=8.4Hz,1H),6.81(br,1H),6.76(d,J=8.8Hz,1H),6.62(s,2H),6.31(br,1H),3.79-3 .76(m,4H),3.68-3.58(m,4H),2.62-2.56(m,1H),2.33(s,3H),2.25(s,3H),1.61(d,J=8.4Hz,1H).
[0336] Other compounds or salts thereof in the present application can be prepared by the methods described in WO 2022 / 199503 A1 and WO 2020 / 168939 A1.
[0337] Experimental evaluation
[0338] Experimental Example 1: RET inhibition experiment
[0339] Experimental method: The inhibitory effect of the compounds of the present invention on the activity of drug-resistant mutant RET enzymes (RET-G810R, RET-G810S, and RET-G810C) was determined according to the instructions of the HTRF KinEASE-TK kit (Cisbio). The three drug-resistant mutant RET enzymes were treated with different concentrations of the test compound (in the compound inhibition rate test: for RET-G810R and RET-G810C, the compound concentrations were 300 and 1000 nM; for RET-G810S, the compound concentrations were 30 and 300 nM. Compound IC 50 During the test: For RET-G810R and RET-G810C, the compound concentration was 1 to 10,000 nM; for RET-G810S, the compound concentration was 0.1 to 10,000 nM, both with 9 concentrations. ) After pre-incubation at room temperature for 30 minutes, the substrate and adenosine triphosphate (ATP) were added to start the reaction. For RET-G810R and RET-G810S, incubate at room temperature for 90 minutes; for RET-G810C, incubate at room temperature for 120 minutes. TK antibody-crypt and antibiotic protein streptavidin-XL665 were added and incubated at room temperature for 60 minutes before detection. The solvent group (DMSO) was used as the negative control, and the buffer group (without RET enzyme) was used as the blank control. The relative inhibitory activity percentage (i.e., inhibition rate) of compounds at different concentrations was calculated according to the following formula:
[0340] Relative inhibitory activity percentage = 1-(different concentration compound groups-blank control) / (negative control-blank control)*100%
[0341] The relative inhibitory activity percentages of the compounds at different concentrations were plotted against the compound concentrations, and the curves were fitted according to the four-parameter model to calculate the IC 50 Value: y=min+(max-min) / (1+(x / IC 50 )^(-Hillslope))
[0342] Where y is the relative inhibitory activity percentage, max and min are the maximum and minimum values of the fitting curve, x is the logarithmic concentration of the compound, and Hillslope is the slope of the curve.
[0343] The experimental results are shown in Table 1-7.
[0344] Table 1. Inhibition rate of the compounds of the present invention on the activity of mutant RET-G810R enzyme at a concentration of 300 nM
[0345] Table 2. IC inhibition of the compounds of the present invention on RET-G810R enzyme 50 (nM)
[0346] It can be seen from Table 1 and Table 2 that the compounds of the present invention have a significant inhibitory effect on RET-G810R enzyme.
[0347] Table 3. Inhibition rate of the compounds of the present invention on the activity of mutant RET-G810S enzyme at a concentration of 300 nM
[0348] Table 4. IC inhibition of the compounds of the present invention on RET-G810S enzyme 50 (nM)
[0349] It can be seen from Table 3 and Table 4 that the compounds of the present invention have a significant inhibitory effect on RET-G810S enzyme.
[0350] Table 5. Inhibition rate of the compounds of the present invention on the activity of mutant RET-G810C enzyme at a concentration of 300 nM
[0351] Table 6. IC inhibition of the compounds of the present invention on RET-G810C enzyme 50 (nM)
[0352] It can be seen from Table 5 and Table 6 that the compounds of the present invention have a significant inhibitory effect on RET-G810C enzyme.
[0353] Table 7. IC inhibition of the compounds of the present invention on RET mutant enzymes 50 (nM)
[0354] As can be seen from Table 7, compound 1-A of the present invention has a significant inhibitory effect on RET-G810R enzyme, RET-G810S enzyme and RET-G810C enzyme.
[0355] Experimental Example 2: Inhibitory effect of compounds on the proliferation of RET mutant cells
[0356] Experimental method: Ba / F3 cells (Ba / F3 KIF5B-RET G810R 、Ba / F3 KIF5B-RET G810S 、 Ba / F3 KIF5B-RET G810C) were seeded into 96-well plates at a rate of 2,000 cells / 95 μl / well. 5 μl of BLU-667, Loxo-292, and Compound 1-A solution were added to each 96-well plate (final concentrations: 1.52–10,000 nM). Additionally, negative control wells (no test compound) and blank control wells (no cells) were set up. After 3 days of incubation at 37°C, 5% CO2, 50 μl / well of Cell Titer Glo reagent was added to lyse the cells. Luminescence signal was measured using a microplate reader, and the percentage of inhibition was calculated.
[0357] Ba / F3 cells (Ba / F3 KIF5B-RET V804E 、Ba / F3 KIF5B-RET V804L 、Ba / F3KIF5B-RET V804M ) were seeded into 96-well plates at 1000 cells / 95 μl / well. 5 μl of BLU-667, Loxo-292, and Compound 1-A solution were added to each 96-well plate (final concentration: 4-25,000 nM). Additionally, negative control wells (no test compound) and blank control wells (no cells) were set up. After 3 days of incubation at 37°C, 5% CO2, 50 μl / well of Cell Titer Glo reagent was added to lyse the cells. Luminescence signal was measured using a microplate reader, and the inhibition rate (%) was calculated.
[0358] Inhibition rate % = [1-(average value of compound group detection signal - average value of blank control signal) / (average value of negative control signal - average value of blank control signal)] * 100%; the inhibition rate % was fitted using the four-parameter equation "log (agonist) vs response-variable slope (four parameters)" in GraphPad Prism 6.0 to calculate the IC 50 .
[0359] Experimental results: See Table 8; The following results show that compound 1-A has an effect on Ba / F3 KIF5B-RET G810R 、Ba / F3 KIF5B-RET G810S 、Ba / F3 KIF5B-RET G810C 、Ba / F3 KIF5B-RET V804E 、Ba / F3 KIF5B-RET V804L 、Ba / F3 KIF5B-RET V804M The cell proliferation inhibition effects were better than those of BLU-667 and Loxo-292.
[0360] Table 8. IC of the compounds against cell proliferation50 (nM)
[0361] Experimental Example 3: Safety Evaluation
[0362] 109 patients with RET-altered tumors were enrolled and treated with compound 1-A of the present invention at six dose levels of 10 mg, 20 mg, 40 mg, 60 mg, 90 mg, and 120 mg once daily. No dose-limiting toxicity (DLT) was observed, and the maximum tolerated dose (MTD) was not reached. Most treatment-related adverse events (TRAEs) (76.1%) were grade 1-2 and reversible, such as increased AST aspartate aminotransferase, increased ALT alanine aminotransferase, increased creatinine, increased bilirubin, anemia, constipation, and headache.
[0363] Experimental Example 4: Treatment of NSCLC, MTC, pancreatic cancer, and ovarian cancer
[0364] 90 patients were recruited, including 70 patients with non-small cell lung cancer (NSCLC), 18 patients with medullary thyroid cancer (MTC), 1 patient with pancreatic cancer, and 1 patient with ovarian cancer. Compound 1-A of the present invention was administered once daily at dose levels of 40-120 mg (40 mg, 60 mg, 90 mg, and 120 mg). The objective response rate (ORR) of the 90 patients was 60%, and the disease control rate (DCR) was 94%.
[0365] Among the 70 NSCLC patients, 26 had not received systemic treatment, 33 had received systemic treatment previously (excluding first-generation selective RET inhibitors), and 11 had received at least first-generation selective RET inhibitors.
[0366] Among 26 NSCLC patients who had not received systemic treatment, including 13 patients with KIF5B-RET fusion-positive, 7 patients with CCDC6-RET fusion-positive, 1 patient with NCOA4-RET fusion-positive, and 1 patient with RELCH-RET fusion-positive, the objective response rate (ORR) was 81% (21 / 26, 1 complete remission (CR), 20 partial remissions (PR), among which all patients with NCOA4-RET fusion-positive and RELCH-RET fusion-positive had partial remissions (PR), and the disease control rate (DCR) was 96%.
[0367] Among 33 NSCLC patients who had previously received systemic treatment (excluding first-generation selective RET inhibitors), 21 patients had KIF5B-RET fusion, 4 patients had CCDC6-RET fusion, and 1 patient had ERC1-RET fusion.
[0368] The median number of previous treatment regimens for the 33 patients was 2, ranging from 1 to 9. Among them, 10 patients (30%) had received anti-PD-1 or PD-L1 systemic treatment, and 5 patients (15%) had previously received MKI inhibitor treatment; among the 33 patients: the objective response rate (ORR) was 70% (23 / 33), 1 patient with ERC1-RET fusion achieved complete remission (CR), and the disease control rate (DCR) was 97%.
[0369] Eleven patients with non-small cell lung cancer (NSCLC) received systemic therapy with a first-generation, selective RET inhibitor. Eight patients were given 90 mg or 120 mg, and three were given 40 mg or 60 mg. Among the eight patients who received 90 mg or 120 mg, three had a partial response (PR), four had stable disease (SD), and seven (88%) patients experienced tumor shrinkage.
[0370] Of the 70 NSCLC patients, 12 had brain metastases, one of whom had received brain radiotherapy. Six patients had measurable brain lesions, with post-treatment reductions of 100%, 100%, 100%, 69%, 47%, and 17% in these patients, respectively, for an overall central nervous system disease control rate (CNSDCR) of 100%.
[0371] The above-described embodiments do not limit the solutions of the present application in any way. In addition to those described herein, various modifications of the present invention will be apparent to those skilled in the art based on the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including all patents, patent applications, journal articles, books and any other disclosures) is incorporated herein by reference in its entirety.
Claims
1. Use of a compound of formula I, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, a cocrystal, a polymorph or a solvate of the compound, or a stable isotope derivative, a metabolite or a prodrug of the compound in the preparation of a medicament for treating RET altered tumors: in: R 1 is selected from 4-10 membered heterocyclyl and 5-10 membered heteroaryl, each of which is optionally substituted by one or more substituents independently selected from the following: hydroxy, halogen, CN, NO2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Halogenated alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy; R 2 Selected from halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 heteroalkyl, 4-10 membered heterocyclyl and 5-10 membered heteroaryl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of hydroxy, halogen, CN, NO2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Halogenated alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy; R 3 Selected from H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Heteroalkyl and C 3-6 cycloalkyl; and X 1 , X 2 and X 3 are each independently selected from CH and N.
2. The use according to claim 1, wherein the RET-altered tumor is a RET+ solid tumor.
3. The use of any one of claims 1-2, wherein the RET-altered tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor resistant solid tumors and neuroendocrine colorectal cancer (neuroendocrine CRC).
4. The use according to any one of claims 1 to 3, wherein the RET-altered tumor is selected from non-small cell lung cancer (NSCLC).
5. The use according to any one of claims 1 to 4, wherein the drug is a drug for the first or second line treatment of RET+ non-small cell lung cancer (NSCLC).
6. The use according to any one of claims 1 to 3, wherein the RET-altered tumor is pancreatic cancer.
7. The use according to any one of claims 1 to 3, wherein the RET-altered tumor is ovarian cancer.
8. The use according to claim 3, wherein the inhibitor is a RET inhibitor or an MKI inhibitor.
9. The use of claim 8, wherein the RET inhibitor is septinib, pralsetinib, SY5007, YP01001 or HA121-28.
10. The use according to claim 8, wherein the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
11. The use according to claim 9, wherein the RET inhibitor is septitinib or pralatinib.
12. The use according to any one of claims 1 to 11, wherein the RET change is a RET mutation or fusion, for example, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion; the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
13. The use according to any one of claims 1 to 12, wherein R 1 is a 5-10 membered heteroaryl group, which is optionally substituted by one or more substituents independently selected from the following: hydroxy, halogen, CN, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy; Preferably, R 1 is a 5-6 membered heteroaryl group, which is optionally substituted by one or more substituents independently selected from the following: halogen, C 1-3 Alkyl and C 3-6 Cycloalkyl; Preferably, R 1 is pyrazolyl, which is optionally substituted by one or more substituents independently selected from the following: halogen, C 1-3 Alkyl (such as methyl) and C 3-6 Cycloalkyl (e.g. cyclopropyl); Preferably, R 1 It is methyl-substituted pyrazolyl (e.g. 5-methyl-1H-pyrazol-3-yl or 1-methyl-1H-pyrazol-4-yl) or cyclopropyl-substituted pyrazolyl (e.g. 5-cyclopropyl-1H-pyrazol-3-yl).
14. The use according to any one of claims 1 to 13, wherein R 2 Selected from halogen (such as Cl), C 1-6 alkyl (eg methyl) and 5-6 membered heteroaryl, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy; Preferably, R 2 is a 5-6 membered heteroaryl group, which is optionally substituted by one or more substituents independently selected from the following: halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy; Preferably, R 2 is a 5-membered heteroaryl group, which is optionally substituted by one or more substituents independently selected from the following: halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl and C 3-6 Cycloalkoxy; Preferably, R 2 is pyrrolyl, pyrazolyl, imidazolyl, furanyl or thiazolyl, which is optionally substituted by one or more substituents independently selected from the group consisting of F, Cl, methyl, Cyclopropyl and -O-cyclopropyl.
15. The use according to any one of claims 1 to 14, wherein R 3 Selected from H, C 1-6 Alkyl and C 3-6 Cycloalkyl; Preferably, R 3 Selected from H and C 1-6 alkyl; Preferably, R 3 It is H or methyl.
16. The use according to any one of claims 1 to 15, wherein: X 1 is CH or N; preferably, X 1 is N; X 2 is CH or N; preferably, X 2 is CH; and / or X 3 is CH or N; preferably, X 3 is N.
17. The method of any one of claims 1 to 16, wherein the compound has a structure shown in Formula IA or Formula IB: Where R 1 , R 2 , R 3 , X 1 and X 2 As defined for Formula I.
18. The use according to any one of claims 1 to 17, wherein the compound is selected from:
19. The use according to any one of claims 1 to 18, wherein the pharmaceutically acceptable salt is a fumarate.
20. The use according to any one of claims 1 to 19, wherein the compound is:
21. The use according to any one of claims 1 to 20, wherein the pharmaceutically acceptable salt of the compound is:
22. A method for treating a RET-altered tumor, comprising administering to an individual a therapeutically effective amount of a compound for use as described in any one of claims 1, 13-21, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound.
23. The method according to claim 22, wherein the RET change is a RET mutation or fusion, for example, the RET fusion is selected from KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion; the RET mutation is selected from G810S, G810R, G810C, V804M, V804L and V804E mutations.
24. The method according to any one of claims 22-23, wherein the RET-altered tumor is selected from non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor resistant solid tumors and neuroendocrine colorectal cancer (neuroendocrine CRC).
25. The method according to claim 24, wherein the inhibitor is a RET inhibitor or a MKI inhibitor.
26. The method according to claim 25, wherein the RET inhibitor is septitinib, pralsetinib, SY5007, YP01001 or HA121-28.
27. The method according to claim 25, wherein the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
28. The method according to claim 27, wherein the MKI inhibitor is anlotinib, cabozantinib or apatinib.
29. The method according to any one of claims 22-28, wherein the therapeutically effective amount is 10-120 mg per day, for example 10 mg, 20 mg, 40 mg, 60 mg, 90 mg, 120 mg, 20-120 mg, 30-120 mg, 40-120 mg, 50-120 mg, 60-120 mg, 70-120 mg, 80-120 mg, 90-120 mg, 100-120 mg or 110-120 mg.
30. The method according to claim 29, wherein the administration cycle is once every 1-7 days.
31. The method of any one of claims 22-30, wherein the subject has an objective response rate (ORR) of at least 60%.
32. The method according to any one of claims 22-31, wherein the individual has not received or has received systemic treatment (systemic pretreated), such as anti-PD1 / PD-L1 treatment, other RET inhibitor treatment (such as seratinib, pralsetinib, SY5007, YP01001 or HA121-28), MKI inhibitor treatment (such as anlotinib, cabozantinib, apatinib or CX1003) or chemotherapy.
33. The method according to any one of claims 22-32, wherein the individual's median prior treatment number is selected from 1-15, such as 1, 2, 3, 4, 5, 6, 7, 8, 9.
34. The method of any one of claims 22-33, wherein the individual has non-small cell lung cancer (NSCLC) with brain metastasis, bone metastasis or liver metastasis.
35. The method according to any one of claims 22-34, wherein the individual has previously received anti-PD1 or PD-L1 systemic treatment.
36. The compound for use according to any one of claims 1, 13-21, the stereoisomers, tautomers or mixtures thereof of the compound, the N-oxide of the compound, the pharmaceutically acceptable salts, cocrystals, polymorphs or solvates of the compound, or the stable isotope derivatives, metabolites or prodrugs of the compound, for treating RET altered tumors.
37. The compound for use according to any one of claims 1, 13-21, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, a cocrystal, a polymorph or a solvate of the compound, or a stable isotope derivative, a metabolite or a prodrug of the compound, for treating RET-altered non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor resistant solid tumors and / or neuroendocrine colorectal cancer (neuroendocrine CRC), optionally, the inhibitor is a RET inhibitor or an MKI inhibitor, further, the RET inhibitor is sepretib, pralsetinib, SY5007, YP01001 or HA121-28; the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
38. A compound for use according to any one of claims 1, 13-21, a stereoisomer, a tautomer or a mixture thereof, an N-oxide of the compound, a pharmaceutically acceptable salt, a cocrystal, a polymorph or a solvate of the compound, or a stable isotope derivative, a metabolite or a prodrug of the compound for treating RET fusion (e.g., KIF5B-RET fusion) or mutation-positive non-small cell lung cancer (NSCLC), medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), pancreatic cancer, ovarian cancer, inhibitor resistant solid tumors and / or neuroendocrine colorectal cancer (neuroendocrine CRC), optionally, the inhibitor is a RET inhibitor or an MKI inhibitor, further, the RET inhibitor is sepretib, pralsetinib, SY5007, YP01001 or HA121-28; the MKI inhibitor is anlotinib, cabozantinib, apatinib or CX1003.
39. The compound for use according to any one of claims 1, 13-21, a stereoisomer, a tautomer or a mixture thereof of the compound, an N-oxide of the compound, a pharmaceutically acceptable salt, cocrystal, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound, for use in one or more lines of treatment of RET+ non-small cell lung cancer (NSCLC), for example, for use in one or more lines of treatment of RET fusion (e.g., KIF5B-RET fusion, CCDC6-RET fusion, NCOA4-RET fusion, RELCH-RET fusion and ERC1-RET fusion) or mutation-positive (e.g., G810S, G810R, G810C, V804M, V804L and V804E mutations) non-small cell lung cancer (NSCLC).
